These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

352 related items for PubMed ID: 18794139

  • 1. Purine-rich box-1-mediated reduced expression of CD20 alters rituximab-induced lysis of chronic lymphocytic leukemia B cells.
    Mankaï A, Bordron A, Renaudineau Y, Martins-Carvalho C, Takahashi S, Ghedira I, Berthou C, Youinou P.
    Cancer Res; 2008 Sep 15; 68(18):7512-9. PubMed ID: 18794139
    [Abstract] [Full Text] [Related]

  • 2. Improvement of rituximab efficiency in chronic lymphocytic leukemia by CpG-mediated upregulation of CD20 expression independently of PU.1.
    Mankaï A, Buhé V, Hammadi M, Youinou P, Ghedira I, Berthou C, Bordron A.
    Ann N Y Acad Sci; 2009 Sep 15; 1173():721-8. PubMed ID: 19758221
    [Abstract] [Full Text] [Related]

  • 3. Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases.
    Chow KU, Sommerlad WD, Boehrer S, Schneider B, Seipelt G, Rummel MJ, Hoelzer D, Mitrou PS, Weidmann E.
    Haematologica; 2002 Jan 15; 87(1):33-43. PubMed ID: 11801463
    [Abstract] [Full Text] [Related]

  • 4. GM-CSF does not increase CD20 antigen expression on chronic lymphocytic leukemia lymphocytes.
    Yağci M, Akar I, Sucak GT, Haznedar R.
    Leuk Res; 2005 Jul 15; 29(7):735-8. PubMed ID: 15927668
    [Abstract] [Full Text] [Related]

  • 5. Apoptotic-regulatory and complement-protecting protein expression in chronic lymphocytic leukemia: relationship to in vivo rituximab resistance.
    Bannerji R, Kitada S, Flinn IW, Pearson M, Young D, Reed JC, Byrd JC.
    J Clin Oncol; 2003 Apr 15; 21(8):1466-71. PubMed ID: 12697868
    [Abstract] [Full Text] [Related]

  • 6. Chronic lymphocytic leukaemia CD20 expression is dependent on the genetic subtype: a study of quantitative flow cytometry and fluorescent in-situ hybridization in 510 patients.
    Tam CS, Otero-Palacios J, Abruzzo LV, Jorgensen JL, Ferrajoli A, Wierda WG, Lerner S, O'Brien S, Keating MJ.
    Br J Haematol; 2008 Apr 15; 141(1):36-40. PubMed ID: 18324964
    [Abstract] [Full Text] [Related]

  • 7. Acquirement of rituximab resistance in lymphoma cell lines is associated with both global CD20 gene and protein down-regulation regulated at the pretranscriptional and posttranscriptional levels.
    Czuczman MS, Olejniczak S, Gowda A, Kotowski A, Binder A, Kaur H, Knight J, Starostik P, Deans J, Hernandez-Ilizaliturri FJ.
    Clin Cancer Res; 2008 Mar 01; 14(5):1561-70. PubMed ID: 18316581
    [Abstract] [Full Text] [Related]

  • 8. Comparison of the in vitro effects of the anti-CD20 antibodies rituximab and GA101 on chronic lymphocytic leukaemia cells.
    Patz M, Isaeva P, Forcob N, Müller B, Frenzel LP, Wendtner CM, Klein C, Umana P, Hallek M, Krause G.
    Br J Haematol; 2011 Feb 01; 152(3):295-306. PubMed ID: 21155758
    [Abstract] [Full Text] [Related]

  • 9. Higher levels of surface CD20 expression on circulating lymphocytes compared with bone marrow and lymph nodes in B-cell chronic lymphocytic leukemia.
    Huh YO, Keating MJ, Saffer HL, Jilani I, Lerner S, Albitar M.
    Am J Clin Pathol; 2001 Sep 01; 116(3):437-43. PubMed ID: 11554173
    [Abstract] [Full Text] [Related]

  • 10. Expression of B cell-associated transcription factors in B-cell precursor acute lymphoblastic leukemia cells: association with PU.1 expression, phenotype, and immunogenotype.
    Nishii K, Kita K, Miwa H, Shikami M, Taniguchi M, Usui E, Katayama N, Shiku H.
    Int J Hematol; 2000 Jun 01; 71(4):372-8. PubMed ID: 10905058
    [Abstract] [Full Text] [Related]

  • 11. PU.1 protein expression has a positive linear association with protein expression of germinal centre B cell genes including BCL-6, CD10, CD20 and CD22: identification of PU.1 putative binding sites in the BCL-6 promotor.
    Torlakovic E, Malecka A, Myklebust JH, Tierens A, Aasheim HC, Nesland JM, Smeland E, Kvaløy S, Delabie J.
    J Pathol; 2005 Jul 01; 206(3):312-9. PubMed ID: 15892171
    [Abstract] [Full Text] [Related]

  • 12. Inverse correlation between Flt3 and PU.1 expression in acute myeloblastic leukemias.
    Inomata M, Takahashi S, Harigae H, Kameoka J, Kaku M, Sasaki T.
    Leuk Res; 2006 Jun 01; 30(6):659-64. PubMed ID: 16271760
    [Abstract] [Full Text] [Related]

  • 13. Antigen modulation followed by quantitative flow cytometry of B-chronic lymphocytic leukemia cells after treatment.
    Kusenda J, Babusíková O.
    Neoplasma; 2004 Jun 01; 51(2):97-102. PubMed ID: 15190418
    [Abstract] [Full Text] [Related]

  • 14. [Density expression of the CD20 antigen on population of tumor cells in patients with chronic B-lymphocyte lymphoproliferative diseases].
    Suková V, Klabusay M, Coupek P, Brychtová Y, Doubek M, Mayer J.
    Cas Lek Cesk; 2006 Jun 01; 145(9):712-6; discussion 716-7. PubMed ID: 17091727
    [Abstract] [Full Text] [Related]

  • 15. Vdelta1 T lymphocytes from B-CLL patients recognize ULBP3 expressed on leukemic B cells and up-regulated by trans-retinoic acid.
    Poggi A, Venturino C, Catellani S, Clavio M, Miglino M, Gobbi M, Steinle A, Ghia P, Stella S, Caligaris-Cappio F, Zocchi MR.
    Cancer Res; 2004 Dec 15; 64(24):9172-9. PubMed ID: 15604289
    [Abstract] [Full Text] [Related]

  • 16. Mechanism of action of type II, glycoengineered, anti-CD20 monoclonal antibody GA101 in B-chronic lymphocytic leukemia whole blood assays in comparison with rituximab and alemtuzumab.
    Bologna L, Gotti E, Manganini M, Rambaldi A, Intermesoli T, Introna M, Golay J.
    J Immunol; 2011 Mar 15; 186(6):3762-9. PubMed ID: 21296976
    [Abstract] [Full Text] [Related]

  • 17. Rituximab in chronic lymphocytic leukemia.
    Jaglowski SM, Byrd JC.
    Semin Hematol; 2010 Apr 15; 47(2):156-69. PubMed ID: 20350663
    [Abstract] [Full Text] [Related]

  • 18. Enhancing the action of rituximab in chronic lymphocytic leukemia by adding fresh frozen plasma: complement/rituximab interactions & clinical results in refractory CLL.
    Klepfish A, Gilles L, Ioannis K, Rachmilewitz EA, Schattner A.
    Ann N Y Acad Sci; 2009 Sep 15; 1173():865-73. PubMed ID: 19758239
    [Abstract] [Full Text] [Related]

  • 19. Chronic lymphocytic leukaemia cells are efficiently killed by an anti-CD20 monoclonal antibody selected for improved engagement of FcgammaRIIIA/CD16.
    de Romeuf C, Dutertre CA, Le Garff-Tavernier M, Fournier N, Gaucher C, Glacet A, Jorieux S, Bihoreau N, Behrens CK, Béliard R, Vieillard V, Cazin B, Bourel D, Prost JF, Teillaud JL, Merle-Béral H.
    Br J Haematol; 2008 Mar 15; 140(6):635-43. PubMed ID: 18302712
    [Abstract] [Full Text] [Related]

  • 20. Superior activity of fusion protein scFvRit:sFasL over cotreatment with rituximab and Fas agonists.
    Bremer E, ten Cate B, Samplonius DF, Mueller N, Wajant H, Stel AJ, Chamuleau M, van de Loosdrecht AA, Stieglmaier J, Fey GH, Helfrich W.
    Cancer Res; 2008 Jan 15; 68(2):597-604. PubMed ID: 18199557
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.